A detailed history of Wellington Management Group LLP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Wellington Management Group LLP holds 62,585 shares of ACAD stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,585
Previous 64,774 3.38%
Holding current value
$1.02 Million
Previous $1.05 Million 8.46%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.14 - $19.14 $33,141 - $41,897
-2,189 Reduced 3.38%
62,585 $963,000
Q2 2024

Aug 13, 2024

BUY
$14.62 - $18.42 $95,132 - $119,858
6,507 Added 11.17%
64,774 $1.05 Million
Q1 2024

May 15, 2024

BUY
$17.79 - $30.86 $1.04 Million - $1.8 Million
58,267 New
58,267 $1.08 Million
Q4 2023

Feb 12, 2024

BUY
$20.78 - $31.77 $810,149 - $1.24 Million
38,987 New
38,987 $1.22 Million
Q1 2023

May 12, 2023

SELL
$16.32 - $20.92 $6.52 Million - $8.35 Million
-399,273 Reduced 25.27%
1,180,637 $22.2 Million
Q4 2022

Feb 13, 2023

SELL
$14.2 - $18.63 $1.89 Million - $2.48 Million
-132,877 Reduced 7.76%
1,579,910 $25.2 Million
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $13.4 Million - $17.3 Million
949,196 Added 124.31%
1,712,787 $28 Million
Q2 2022

Aug 15, 2022

BUY
$13.01 - $27.22 $9.93 Million - $20.8 Million
763,591 New
763,591 $10.8 Million
Q3 2020

Nov 16, 2020

SELL
$36.42 - $57.0 $24.7 Million - $38.6 Million
-677,709 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$39.26 - $52.73 $5.85 Million - $7.85 Million
-148,952 Reduced 18.02%
677,709 $32.8 Million
Q1 2020

May 14, 2020

BUY
$31.65 - $46.87 $5.34 Million - $7.91 Million
168,716 Added 25.64%
826,661 $34.9 Million
Q4 2019

Feb 11, 2020

BUY
$36.21 - $51.4 $23.8 Million - $33.8 Million
657,945 New
657,945 $28.1 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.63B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.